<DOC>
	<DOCNO>NCT02379468</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Pedyphar® ointment heal foot ulceration diabetic patient .</brief_summary>
	<brief_title>Efficacy &amp; Safety Pedyphar Ointment Diabetic Foot Ulcer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Pantothenic Acid</mesh_term>
	<criteria>1 . Written inform consent sign date study subject . 2 . Male Female patient . 3 . Age ≥18 year old ≤ 70 year old . 4 . Clinical diagnosis Diabetes Mellitus Type I II diabetic foot ulcer . A past history Diabetes Mellitus and/or use antidiabetic medication treatment Diabetes Mellitus diabetic foot ulcer sufficient . 5 . Presence 1 DFU , less 15 cm big diameter , Texas University grade ≤ 2 ≤ grade 2 accord Wagner Grading system . 6 . Diabetic foot ulcer present least 4 week 2 year prior screen . 7 . If Diabetic Foot Ulcer Infection , It must : 1 . Mild ( Presence ≥ 2 manifestation inflammation ( purulence , erythema , pain , tenderness , warmth , induration ) , cellulitis/erythema extend ≤ 2 cm around ulcer , infection limit skin superficial subcutaneous tissue ; local complication systemic illness ) . Or : 2 . Moderate Infection ( ) patient systemically well metabolically stable ≥1 follow characteristic : cellulitis extend &gt; 2 cm , lymphangitic streaking , spread beneath superficial fascia , deeptissue abscess , gangrene , involvement muscle , tendon , joint bone . 8 . If subject female childbearing potential , agree use medically acceptable physical barrier method contraceptive treatment phase . 9 . Be willing able participate study outpatient , make require visit study center treatment period , comply study requirement . 10 . Receiving medical care diabetes . 1 . DFU Texas score &gt; 2 &gt; grade 2 accord Wagner Grading system . 2 . Severe Infected DFU clinical paraclinical finding suggest osteomyelitis ( Infection patient systemic toxicity metabolic instability ( e.g. , fever , chill , tachycardia , hypotension , confusion , vomit , leukocytosis , acidosis , severe hyperglycemia , azotemia ) 3 . Clinically define document severe arterial disease . 4 . History radiation therapy ulcer site . 5 . If study subject Foot Ulcer diabetic pathophysiology . 6 . Receiving corticosteroid immune suppressive agent . 7 . History immunevascular disease . 8 . Known hypersensitivity component Pedyphar® Panthenol . 9 . Patients undergoing hemodialysis . 10 . Insufficient blood supply Lower Limb ( anklebrachial index &lt; 0.9 ) . 11 . Clinical finding suggest complicate venous insufficiency LL . Edema [ Hyper pigmentation , Venous dermatitis , Chronic cellulitis , Cutaneous infarction ( atrophie blanche ) , Ulceration ] 12 . Received treatment investigational drug device within last 30 day 13 . Unable comply procedure describe protocol 14 . History moderate severe ischemic heart disease history congestive heart failure , myocardial infarction within previous 6 month . 15 . Patients history major hematological , renal hepatic abnormality . 16 . Mentally neurologically disable patient consider fit approve participation study . 17 . Refusal give inform consent . 18 . Pregnant Breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Foot</keyword>
	<keyword>Ulcer</keyword>
</DOC>